Compare Invesco DB Oil Fund (DBO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs Incyte Corporation — how do they compare? Invesco DB Oil Fund trades at $24.12 (market cap $255.13M), while Incyte Corporation trades at $113.22 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 89.6× Invesco DB Oil Fund's market cap, and Invesco DB Oil Fund is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Oil Fund for 31 Days and Incyte Corporation for 33 Days on average.
| DBO | INCY | |
|---|---|---|
Market Cap | $255.13M | $22.85B |
Volume | 562,167 | 1,927,029 |
Sector | Commodities - Energy | Health |
52-Week High | $26.35 | $129.93 |
52-Week Low | $11.98 | $83.80 |
Typical Hold Time | 31 Days | 33 Days |
Enterprise Value | — | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $23.54, down 0.42% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance at $24 and support at $23, while moving averages signal bearish momentum. Recent oil market developments, including Middle East tensions and OPEC+ production decisions, create a volatile backdrop for energy stocks.
The outlook remains cautious given geopolitical risks and mixed oil price signals. Investment opportunities exist if supply disruptions persist, but risks include potential price declines from strategic reserve releases and ongoing legal challenges facing the oil industry.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
